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Abstract The literature of the last 4 years confirms that the
anti-CCP2 test is a very useful marker for the early and
specific diagnosis of rheumatoid arthritis (RA). The anti-
CCP2 test is very specific for RA (95–99%) and has
sensitivity comparable to that of the rheumatoid factor (70–
75%). The antibodies can be detected very early in the
disease and can be used as an indicator for the progression
and prognosis of RA. In this review, these interesting




The presence of autoantibodies in the serum of patients is a
very typical phenomenon for autoimmune diseases. Most of
these autoantibodies, however, can also be detected in
patients with other conditions and are therefore not specific.
A typical example is the rheumatoid factor (RF), which is
present in most inflammatory conditions. However, in some
cases, autoantibodies can give the clinician a more precise
indication of the type of underlying disease because they
occur specifically in a certain disease. For example, anti-Sm
antibodies are linked almost exclusively to systemic lupus
erythematosus (SLE); whereas anti-DNA topoisomerase-I
antibodies are typically present in scleroderma patients.
Among the most disease-specific autoantibodies described
are the so-called ACPA (anti-citrullinated protein/peptide
antibodies). These antibodies occur specifically in RA and
can be measured most conveniently via the anti-CCP (anti-
cyclic citrullinated peptide) antibody test.
ThefirstgenerationCCPtest(CCP1)usedinearlydiagnostic
studies (2000–2001) contained a single cyclic citrullinated
peptide derived from filaggrin as the substrate [1]. It could
detect ACPA in 68% of patients with established RAwith a
very high specificity (98%). Because filaggrin is not
expressed in the synovium, it is most likely not the natural
citrullinated antigen for ACPA. Other peptides, not related
to filaggrin, could therefore potentially provide better
epitopes for detection of ACPA. Via screening of a number
of peptide libraries, novel citrullinated peptides were
obtained and incorporated into a second generation CCP
test (CCP2). This test is commercially available, and as all
companies use the same type of CCP2 peptides, standard-
ization is achieved quite easily. The diagnostic properties of
this test will be discussed below.
The CCP2 Test is Sensitive and Highly Specific for RA
Since its appearance on the market in the second half of
2002, the diagnostic properties of the CCP2 test have been
studied by many laboratories. This resulted in more than
120 publications dealing with this subject. The accumulated
data, including only papers that appeared in PubMed till
December 2006, are given in Table 1. It is clear that the
accumulated data confirm the earliest reports on specificity
and sensitivity of the CCP2 test. The anti-CCP2 test
demonstrates an RF-like sensitivity with a very high
specificity for RA (see also recent reviews: [2, 3]). It is
also commonly recognized that anti-CCP2 antibody may be
present in up to 40% of RF-negative RA sera [4, 5].
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e-mail: w.vanvenrooij@ncmls.ru.nlThe anti-CCP2 test enables clinicians to distinguish RA
patients from other arthritic diseases, especially in cases
where the RF test is not discriminative. This is, for
example, the case with chronic hepatitis C virus (HCV)
infection, a disease that can easily be misdiagnosed as it
often reveals RA-like arthropathies and, in many cases, is
accompanied by a positive RF. Several examples of such
studies are given in recent reviews on this subject [6].
Recently, there is also an interest to compare the
diagnostic potential of anti-CCP2 with novel tests based
on the use of a citrullinated antigen (for example, MCV=
anti-mutated citrullinated vimentin [7], CPA=citrullinated
protein antibodies, VCP=anti-viral citrullinated protein [8],
antihuman fibrinogen alpha [9, 10], and CCP3 [11]). For a
reliable comparison of these tests, it is essential that their
performance is assessed under the same conditions, e.g., the
sensitivities of the tests should be determined at the same
level of specificity. Good examples of such stratified
studies have been carried out recently by van der Cruijssen
et al. [10] and Dejaco et al. [7]. For example, Dejaco et al.
[7] showed, in a large cohort of patients (>600), that at a
specificity of 98.7%, being the specificity of the anti-CCP2
test, the sensitivity of the anti-MCV test is 53.7% as
opposed to 70.1% for the anti-CCP test. Coenen et al. [11]
compared several commercial tests, including a very recent
CCP3 test from Inova. At the cut-offs recommended by the
various manufacturers, the positive predictive value of the
three commercial CCP2 tests is about 90% with a
specificity of around 96%. The specificity of the other tests
(CCP3=88%, MCV=90%, CPA=94%) is lower as are their
positive predictive values [11]. These numbers may
improve a little bit when the cut-off values are adjusted to
more realistic data; nevertheless, the data allow the statement
that, in absolute percentages, none of thetests performs better
than the anti-CCP2 test. They also seem to indicate that some
tests detect RA patient groups that are negative in the anti-
CCPtest, illustrating again that theautoantibody repertoire of
RA patients is very heterogeneous.
Another risk for the specificity of a test that is based on a
citrullinated antigen is the possibility that antibodies are not
directed exclusively to the citrulline-containing epitope but
also to other possibly overlapping epitopes present in the
substrate antigen. This is particularly important when
citrullinated versions of proteins like vimentin or fibrinogen
are used. For example, it is known that antibodies to
vimentin are present in several diseases different from RA
[12, 13]. This particular problem has been addressed for
CCP2 by Vannini et al. [14]. They used ELISA plates
containing the control CCP2 antigens (Arg instead of Cit in
the same peptide context), produced and made available by
Euro-Diagnostica, Arnhem, The Netherlands, in parallel to
the normal CCP2 test. The results of these comparative
studies showed that in RA and most non-RA rheumatic
disease sera, anti-CCP reactivity indeed is citrulline-
dependent. However, in some patients, particularly autoim-
mune hepatitis patients, citrulline-independent reactivity
with the antigen may occur. A positive CCP test in a
rheumatic disease (almost always citrulline-specific) may
thus suggest the future development of RA as has been
suggested by several studies [15, 16]. A positive test in a
nonrheumatic disease (very often not citrulline-specific), for
example, liver disease, should be interpreted with care [14].
Anti-CCP2 Antibodies are Present Early in Disease
and have Predictive Potential
Because RA patients at first presentation often do not fulfill
the criteria for the diagnosis/classification of RA, an early,
highly predictive marker would greatly assist the clinician
in reaching an early diagnosis. There are several studies
indicating that the anti-CCP2 test provides this help
(reviewed by [2]).
In the recently published EULAR recommendations for
the management of early arthritis [16], a list of factors has
been proposed that predict persistent and erosive disease.
These factors include: number of swollen and tender joints,
ESR or CRP, level of RF and anti-CCP antibodies, and
radiographic erosions. Most of these factors were also
mentioned as being important in the prediction of early
erosive RA (Visser et al. [17]). Subsequent studies by the
same group gave an indication of the relative importance of
these factors. When expressed as odds ratios (OR), the data
was as follows: arthritis of three or more joints, 5.0;
Table 1 Cumulative anti-CCP2
diagnostic data published
between 2002 and 2006
In total, 122 independent studies
were included. The selection
for early RA has been adopted
from the original reports.
Patient group Number CCP2+ Sensitivity (%) Specificity (%)
RA total 14,183 10,135 71.5
Early 3,876 2,365 61.0
Established 10,307 7,770 75.4
Controls 15,156 683 4.5 95.6
Non-RA 11,502 647 5.6 94.4
Healthy 3,654 36 1.0 99.0
Clinic Rev Allerg Immunol (2008) 34:36–39 37 37radiographic erosions, 8.7; positive IgM-RF, 1.7; and
positive anti-CCP2, 38.6 [18]. These and other data (see
also [19]) clearly show that the presence of anti-CCP
antibodies is an important and independent prognostic
factor for radiographic progression in not only early
arthritis but also in early rheumatoid arthritis [16, 20].
Recently, it has also been shown that IgM-CCP is
present in early samples from both patients with undiffer-
entiated arthritis (UA) and patients with RA as well as in
follow-up samples from patients with RA. These data
indicate the development of the anti-CCP isotype repertoire
into full usage early in the course of arthritis and a
continuous (re)activation of the RA-specific anti-CCP
response during the further development of the disease [21].
It is, however, evident that besides the clinical and
laboratory parameters mentioned above, some genetic
factors are important as well. The effect of the HLA
shared-epitope alleles on the development of ACPA has
been firmly established. Citrullination is typically a process
that occurs in apoptotic cells. Because such dying cells are
generally removed from the environment via clearance by
phagocytes, a process that is regulated by many genes, the
immune system will normally not encounter citrullinated
proteins. However, it has been shown that during inflam-
mation, citrullinated proteins are detectable in the inflamed
tissue, both in RA and non-RA patients [22]. This is
probably caused by inefficient clearance of the massive
numbers of dying cells, a process already described to
occur in SLE [23]. This inefficient clearing could, in
principal, also be the consequence of altered genes, i.e.,
the genetic background. The mere presence of citrullinated
antigens in inflamed synovial tissue does not necessarily
result in the occurrence of anti-CCP antibodies in serum or
synovial fluid, neither in humans nor in mouse models of
arthritis [24, 22]. Hill et al. [25] showed that the generation
of anticitrulline antibody in mice actually is linked to the
expression of the RA shared epitope (SE), and a similar link
was also found in patients because the combination of SE,
and anti-CCP has a very high predictive value for the future
development of RA [26]. The specific structure of HLA
molecules obviously plays an important role in the
induction of autoimmunity to citrullinated proteins. These
studies were extended by Huizinga et al. [27] who found
that HLA-DRB1 alleles encoding the SE were only
associated with anti-CCP positive RA and not with anti-
CCP negative RA. In contrast, anti-CCP negative RA
appeared to be associated with HLA-DR3 [28]. Therefore,
the presence of citrullinated antigens, together with the
appropriate genetic background (the SE and probably other
types of HLA), appears to be the minimum requirement for
an immune response to citrullinated polypeptides to be
generated [29]. Next to that, other sensitizing genetic
settings resulting from polymorphisms (e.g., PTPN22
[30]) might, given their association, aid in triggering of
ACPA.
Conclusions and Future Perspectives
The present literature describes and confirms that the anti-
CCP2 test is a very useful marker for the early and accurate
diagnosis of RA. Anti-CCP antibody is very specific for
RA and has a sensitivity comparable to that of RF. These
antibodies can be detected very early in disease and may be
used as an indicator for the progression and prognosis of
RA. Initially, the test was available principally as a manual
ELISA method through Euro-Diagnostica and Axis-Shield
and their partners. More recently, fully automated anti-CCP
assays have also been made available from Phadia (UniCap
Elia CCP) and Abbott Diagnostics (AxSYM anti-CCP). A
very novel format is the CCPoint, a Point-of-Care test for
the detection of these antibodies in whole blood in 10 min
[31]. A small drop of whole blood is applied onto the
sample well followed by the addition of four drops of
running buffer. After 10 min, the result is read by visual
inspection of the detection zone for staining of the antigen
line. As no special equipment is required to perform the
assay, this test will bring the detection of anti-CCP
antibodies into the office of the family doctor, facilitating
a very fast referral to the rheumatologist when the test gives
a positive answer. Such new applications will undoubtedly
further enhance the utility of the anti-CCP autoantibody
system in clinical practice.
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